|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
1R21CA206013-01A1
|
$203,400
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas
|
5R21CA208463-02
|
$174,000
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-02
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-04
|
$765,544
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
5R01CA185062-04
|
$312,304
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
|
5R01CA185486-04
|
$517,690
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-03
|
$553,740
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-03S1
|
$63,140
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
5P20CA192994-03
|
$288,919
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
5P20CA192996-03
|
$154,908
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-08
|
$1,192,222
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
5-hydroxymethylcytosine in human cancer
|
5R01CA160965-06
|
$394,250
|
PFEIFER, GERD
|
VAN ANDEL RESEARCH INSTITUTE
|
|
A cell-based liquid biopsy approach for early pancreatic cancer detection
|
5F32CA196120-03
|
$57,066
|
BHAGWAT, NEHA
|
UNIVERSITY OF PENNSYLVANIA
|
|
A Clinical Validation Center for Early Detection of Pancreatic Cancer
|
5U01CA200468-02
|
$1,759,344
|
MAITRA, ANIRBAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120-02060
|
$169,821
|
Rothman, Nat
|
DCEG (NCI)
|
|
A CROSS-SECTIONAL STUDY OF OCCUPATIONAL EXPOSURE TO TRICHLOROETHYLENE, CHROMOS
|
ZIA CP010121-10363
|
$11,686
|
Lan, Qing
|
DCEG (NCI)
|
|
A differentiation-based mechanism limiting pancreatic tumor initiation
|
5F30CA192819-03
|
$40,653
|
KRAH, NATHAN
|
UNIVERSITY OF UTAH
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
2U01CA164974-07
|
$2,195,369
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5UM1CA164974-06
|
$639,740
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A highly specific NIRF/PET probe for the detection of cancer and metastases
|
1R43CA210854-01A1
|
$224,958
|
Yang, Xinlin
|
IMOL RADIOPHARMACEUTICALS, LLC
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
5R01CA190843-03
|
$311,458
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-04
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-03
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-04
|
$254,171
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Positron Emission Tomography Strategy for Early Detection and Treatment Monitoring of Graft-versus-host Disease
|
5R01CA201719-02
|
$361,504
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
1R44CA221513-01
|
$1,017,478
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
5U01CA187508-03
|
$590,572
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A rapid spontaneous murine model of CN-AML
|
3R01CA196658-02S1
|
$234,525
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A rapid spontaneous murine model of CN-AML
|
5R01CA196658-02
|
$575,500
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$317,262
|
Tosato, Giovanna
|
CCR (NCI)
|
|
A Scalable Blood-based Pancreatic Cancer Test for High-Risk Screening
|
1R43CA213863-01A1
|
$225,001
|
FREEDMAN, DAVID
|
NANOVIEW DIAGNOSTICS, INC.
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$703,174
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$703,174
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Aberrant signaling in acute myeloid leukemia
|
3R01CA204396-02S1
|
$232,133
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-02
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$380,330
|
Aplan, Peter
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|